The osteosarcoma treatment pipeline is gradually expanding, with emerging therapies such as OST-HER2 (OS Therapies), DANYELZA (naxitamab-gqgk; SERB Pharmaceutical), Vactosertib (MedPacto), Risvutatug rezetecan (GSK), Olaparib with Ceralaserti (AstraZeneca), OMO-103 (Peptomyc),...